Showing results (41-50 of 51) with videos related to
Sort By:
Pageof 6
Journal of the European Academy of Dermatology and Venereology : JEADV|August 3, 2022
Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearanceK Reich, K B Gordon, B Strober, et al.Academic Medicine : Journal of the Association of American Medical Colleges|October 1, 2019
Understanding Debriefing: A Qualitative Study of Event Reconstruction at an Academic Medical CenterRachel E Sweeney, Justin T Clapp, Alexander F Arriaga, et al.Anesthesiology|March 5, 2019
Failure to Debrief after Critical Events in Anesthesia Is Associated with Failures in Communication during the EventAlexander F Arriaga, Rachel E Sweeney, Justin T Clapp, et al.Teaching and Learning in Medicine|April 25, 2023
Does Masked Interviewing Encourage Holistic Review in Residency Selection? A Mixed-Methods StudyJustin T Clapp, Sarah J Heins, Timothy G Gaulton, et al.The British Journal of Dermatology|October 15, 2021
Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasisK B Gordon, M Lebwohl, K A Papp, et al.The British Journal of Dermatology|June 9, 2021
Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2K Reich, K B Gordon, B E Strober, et al.Bulletin of Experimental Biology and Medicine|September 12, 2022
Differential Markers of Subpopulations of Epithelial Cells of the Larynx in Squamous Cell CarcinomaI V Arutyunyan, A G Soboleva, K B Gordon, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|February 13, 2017
Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasisA Blauvelt, K A Papp, H Sofen, et al.The Journal of Dermatological Treatment|May 1, 2020
Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trialsK B Gordon, K Reich, J J Crowley, et al.The Journal of Investigative Dermatology|February 11, 1998
Epitope spreading: lessons from autoimmune skin diseasesL S Chan, C J Vanderlugt, T Hashimoto, et al.Pageof 6